EBITDA at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's EBITDA?
- 4D Molecular Therapeutics (FDMT) reported EBITDA of -$72.35M in Q1 2026.
- How has 4D Molecular Therapeutics's EBITDA changed year-over-year?
- 4D Molecular Therapeutics's EBITDA decreased by 37.6% year-over-year, from -$52.57M to -$72.35M.
- What is the long-term trend for 4D Molecular Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's EBITDA has grown at a 24.8% compound annual growth rate (CAGR), from -$69.81M to -$169.57M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.